Trastuzumab emtansine (T-DM1)
Kadcyla · Antibody-drug conjugate (HER2/DM1)
Rare nodular regenerative TMA-like signals.
Kyprolis · Carfil
Proteasome inhibitor · approved 2012 · 13 citations · FAERS AKI reporting ROR 3.11 (95% CI 2.91–3.32, 909 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The proteasome inhibitor with a real renal signature — common AKI, thrombotic microangiopathy and hypertension in myeloma.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Renal complications are common and a recognized class concern: in a 114-patient real-world cohort, ~17% had renal complications not related to myeloma progression (TMA in 6 patients, ~5%; albuminuria >1 g/day ~6%; otherwise-unexplained grade >=3 AKI in another 6 patients), occurring mostly early and unpredictably. On the prospective CARDAMON trial 8 patients experienced TMA (6 of 8 hypertensive at presentation, 7 of 8 with AKI); after a protocol amendment adding aggressive hypertension management, carfilzomib step-up dosing at the start of maintenance and dexamethasone premedication, the rate fell from 4.2 to 1.6 events per 1,000 patient-cycles with no further maintenance events. Pharmacovigilance (FAERS) shows carfilzomib carries by far the strongest TMA signal among proteasome inhibitors.Source: Fotiou et al., Blood Cancer J 2020 (114-patient cohort)
Often early (first cycles) but TMA can also appear later, including after a break and re-escalation.
Distilled from: “Variable — frequently early (first cycles), but TMA can also appear later, sometimes after a treatment break and re-escalation.”
TMA has recurred after a treatment break and re-escalation — reintroduce only with close monitoring.
Hematologic and renal recovery diverge, and the largest series (37 cases) is explicit that treatment did not drive either: TMA resolved in most patients (n = 34, 94%), yet 12 (44%) were still KDIGO stage 3 AKI at discharge — and of the patients given therapeutic plasma exchange (51%), corticosteroids (38%) or eculizumab (50%), "none of these treatments demonstrated a significant impact on outcomes". Stopping the drug is the intervention with a rationale; the rest is supportive.PMID 38658194 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsGermline / pharmacogenomic variants that shift an individual's risk of this agent's kidney injury. Research-grade — not routine clinical testing.
Germline deletion in the complement Factor H-related gene region increases susceptibility to carfilzomib-induced complement-mediated thrombotic microangiopathy (renal TMA/AKI); ~2.3-fold enrichment vs general population in carfilzomib-TMA patients. PMID 36849497 (opens PubMed in a new tab)
Germline complement alternative-pathway dysregulation is enriched in myeloma patients who develop carfilzomib-induced TMA versus non-TMA controls, predisposing to complement-mediated renal endothelial injury (TMA/AKI). PMID 35743426 (opens PubMed in a new tab)
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
TMA in 6 of 114 (5%) patients in a real-world relapsed/refractory myeloma cohort; renal complications not related to myeloma progression in 17%.
Grade 3-5 kidney toxicity 8.3% (21.3% any grade) in RCT meta-analysis, predominantly AKI
All-grade hypertension 13.2%, high-grade 5.3% (45-trial meta-analysis)
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Thrombotic Microangiopathy strikes: Glomerulus, Vasculature / Endothelium.
Thrombotic Microangiopathy
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Irreversible (epoxyketone) inhibitor of the chymotrypsin-like activity of the 20S proteasome, causing accumulation of misfolded/ubiquitinated proteins, ER stress and apoptosis in myeloma cells. Used in relapsed/refractory multiple myeloma.
Class-level context for the major non-renal toxicities of the Proteasome inhibitor class.
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Hematologic
Cytopenias, thrombosis, TMA
9 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Kidney rows of the label's dosage tables
From the KYPROLIS label (Jun 2025) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. A cell marked fn carries one of those footnotes on the label. Educational only, not medical advice.
| Serum creatinine greater than or equal to 2 × baseline, or Creatinine clearance less than 15 mL/min, or creatinine clearance decreases to less than or equal to 50% of baseline, or need for hemodialysis | Withhold dose and continue monitoring renal function (serum creatinine or creatinine clearance) If attributable to Kyprolis, resume when renal function has recovered to within 25% of baseline; start at 1 dose level reduction If not attributable to Kyprolis, dosing may be resumed at the discretion of the healthcare provider For patients on hemodialysis receiving Kyprolis, the dose is to be administered after the hemodialysis procedurefn |
Everything below is FAERS — adverse events someone chose to report, about 28,379 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
4,434 of 28,379 reports
Reported with hospitalization
9,498 of 28,379 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1,088 of the 28,379 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Carfilzomib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Kadcyla · Antibody-drug conjugate (HER2/DM1)
Rare nodular regenerative TMA-like signals.
Velcade · Proteasome inhibitor
Rare TMA; reverses myeloma cast nephropathy.
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
VEGFR TKI
Hypertension as an on-target marker; proteinuria.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Carfilzomib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Carfilzomib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 65 clinical records among all 80 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.